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Sepsis continues to cause significant morbidity and mortality in critically ill patients. Studies of patients and
animal models have revealed that changes in the immune response during sepsis play a decisive role in the outcome.
Using a clinically relevant two-hit model of sepsis, i.e., cecal ligation and puncture (CLP) followed by the induction
of Pseudomonas aeruginosa pneumonia, we characterized the host immune response. Second, AS101 [ammonium
trichloro(dioxoethylene-o,o)tellurate], a compound that blocks interleukin 10 (IL-10), a key mediator of immuno-
suppression in sepsis, was tested for its ability to reverse immunoparalysis and improve survival. Mice subjected to
pneumonia following CLP had different survival rates depending upon the timing of the secondary injury. Animals
challenged with P. aeruginosa at 4 days post-CLP had40% survival, whereas animals challenged at 7 days had 85%
survival. This improvement in survival was associated with decreased lymphocyte apoptosis, restoration of innate
cell populations, increased proinflammatory cytokines, and restoration of gamma interferon (IFN-) production by
stimulated splenocytes. These animals also showed significantly less P. aeruginosa growth from blood and bron-
choalveolar lavage fluid. Importantly, AS101 improved survival after secondary injury 4 days following CLP. This
increased survival was associated with many of the same findings observed in the 7-day group, i.e., restoration of
IFN- production, increased proinflammatory cytokines, and decreased bacterial growth. Collectively, these studies
demonstrate that immunosuppression following initial septic insult increases susceptibility to secondary infection.
However, by 7 days post-CLP, the host’s immune system has recovered sufficiently to mount an effective immune
response. Modulation of the immunosuppressive phase of sepsis may aid in the development of new therapeutic
strategies.
Severe sepsis with resultant organ dysfunction remains a life-
threatening condition that is associated with significant morbidity
and mortality. Understanding the changes in the host’s immune
response throughout the course of illness remains a major obsta-
cle to the development of effective strategies in the treatment of
sepsis. Sepsis results in a cascade of events, including the produc-
tion of pro- and anti-inflammatory cytokines and a shift from a
Th1 to a Th2 immune phenotype, as well as the induction of
apoptosis of immune effector cells (5, 10, 17, 25). This immune
response in sepsis has dramatic and deleterious effects on the
host’s ability to eradicate the infection.
The early phase of sepsis is dominated by a hyperinflammatory
state mediated by systemic production of inflammatory cytokines,
including interleukin 1 (IL-1), IL-6, tumor necrosis factor alpha
(TNF-), and gamma interferon (IFN-) (3, 7, 31). This hyper-
inflammatory “cytokine storm” may lead to significant end-organ
damage and death in a subset of patients. Concomitant with the
initial hyperinflammatory response is a nearly simultaneous pro-
duction of anti-inflammatory cytokines, including IL-10, that
serve to balance the inflammatory state. As a result, the majority
of patients survive the initial hyperinflammatory state and
progress to a protracted period of immune suppression (3, 7, 9,
28, 31). Animal studies, as well as recent human studies, have
highlighted the importance of delayed sepsis-induced immuno-
suppression and its contribution to the mortality of the syndrome
(14). Several researchers have shown that the levels of both proin-
flammatory and anti-inflammatory cytokines can be correlated
with the severity of illness (26, 27, 29). For example, IL-10, a
potent anti-inflammatory cytokine, has been shown to predict
poor prognosis in patients with sepsis, and modulation of IL-10 in
selected animal models of sepsis improved survival (15, 16, 34; M.
Ariefdjohan, K. Queensland, L. Weitzel, D. Heyland, and P. Wis-
chmeyer, presented at the 32nd Annual Conference on Shock,
San Antonio, TX, 2009). Conversely, there is also evidence that
downregulation of IL-10 or absence of IL-10 (IL-10-null mice) is
detrimental in some animal models of infection (21). These ap-
parently contradictory findings point to the importance of under-
standing the overall balance between pro- and anti-inflammatory
cytokines and their effects upon the hypo-/hyperinflammatory
axis.
For decades, researchers have tried to develop new thera-
peutic strategies to treat sepsis and the resultant multiorgan
failure. Unfortunately the majority, if not all, of these thera-
peutic modalities have failed, including those therapies that
have shown significant promise in animal models (32). As a
result of the protracted immunosuppression, patients with sep-
sis face a significant risk of developing secondary infections.
Researchers have demonstrated this increased risk in both
septic patients and animal models of sepsis (19, 22). However,
there is little understanding of the duration of immune sup-
pression and how the timing of secondary injury impacts overall
mortality. Having previously developed a clinically relevant mu-
rine model of secondary infection, i.e., cecal ligation and puncture
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(CLP) followed by Pseudomonas aeruginosa pneumonia infection,
our first aim was to further characterize the extent and duration
of immune suppression following primary (CLP) injury in light of
resistance to and recovery from secondary (P. aeruginosa) insult
(22). In our previous work, we had established increased mortality
in animals infected with either P. aeruginosa or S. pneumoniae 3
days following CLP (22). This more recent work set out to un-
derstand how the immune response evolves over time by evalu-
ating the changes in the cellular composition of the spleen and the
ability of the host to produce inflammatory cytokines and respond
to a secondary insult over the first 7 days following CLP. Next, we
examined the possibility of manipulating the cytokine milieu fol-
lowing primary injury. In particular, we used the immune modu-
lator AS101 [ammonium trichloro(dioxoethylene-o,o)tellurate],
a compound known to block synthesis of IL-10 and to increase a
number of proinflammatory cytokines. AS101 has been shown be
effective in multiple models, including both viral and bacterial
infections, autoimmune diseases, and cancer (16, 34, 35). Due to
its ability to modulate the inflammatory axis, we evaluated the
potentially prosurvival effects of AS101 in a two-hit model of
sepsis.
MATERIALS AND METHODS
Study design. (i) CLP model of sepsis. The CLP model of sepsis as developed
by Chaudry et al. and as modified for use in mice by Baker et al. was employed
as the initial septic insult (1, 2). Male C57BL/6 mice (Jackson Laboratory, Bar
Harbor, ME), 20 to 25 g body weight and 8 to 10 weeks of age, were housed
for at least 1 week prior to use. The mice were anesthetized with isoflurane (5%
induction, 2% maintenance), and the abdomen was prepped and draped. A
midline laparotomy was performed, and the cecum was identified and exterior-
ized. The distal one-third of the cecum was ligated and punctured once with a
30-gauge needle. This level of injury was utilized in order to create a prolonged
infection with relatively low mortality (10%). The abdomen was closed in two
layers, and 1 ml of 0.9% saline mixed with 0.05 mg/kg of body weight buprenor-
phine (Hospira Inc., Lake Forest, IL) was administered subcutaneously (s.c.) to
replace third-space losses and provide pain control. A single dose of imipenem
(25 mg/kg) was given s.c. 1 h post-CLP. Controls, i.e., sham-operated mice, were
treated identically, except the cecum was neither ligated nor punctured. One day
post-CLP, 1 ml of 0.9% saline was given s.c. to all animals.
(ii) The “second-hit” pneumonia model of sepsis. At 4 or 7 days post-CLP, the
surviving mice were again anesthetized with isoflurane and held vertically in a
“head-up” position. Using a pipette, 25 l of a bacterial suspension (0.3 A600 
5  108 CFU/ml; 0.5 A600  1  109 CFU/ml; 0.7 A600  3  109 CFU/ml) was
slowly injected intranasally (divided equally between the nares) and observed to
be aspirated on inhalation and held in position for 1 min. The control protocol
for the pneumonia model consisted of mice that were treated identically except
that normal saline was instilled intranasally instead of the bacterial suspension.
Survival was recorded for 7 days following pneumonia. For all acute studies, 25
l of the 0.5-A600 P. aeruginosa suspension was used as the secondary injury.
Microbiologic preparation. The bacteria were prepared as previously de-
scribed (8). P. aeruginosa was selected because it is a Gram-negative bacterium
that is one of the most common causes of nosocomial pneumonia (6). Briefly, P.
aeruginosa (ATCC 27853) was grown overnight at 35°C with constant shaking to
stationary phase in Trypticase soy broth. Bacteria were harvested by centrifuga-
tion, and the pellet was washed and resuspended in sterile phosphate-buffered
saline (PBS) to absorbencies of 0.3, 0.5, and 0.7 A600. Serial dilution and colony
counts of inocula corresponded to densities of 5 108 CFU/ml, 1 109 CFU/ml,
and 3  109 CFU/ml, respectively.
Cytokine analysis. Whole blood was drawn from all mice at the time of
harvest. Plasma was collected for cytokine analysis and analyzed in duplicate
using a cytometric bead array for 23 cytokines. The cytokines measured were
IL-1, IL-1	, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13,
IL-15, IL-17, IL-18, eotaxin, granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-, KC,
monocyte chemoattractant protein 1 (MCP-1), MIP-1, RANTES, and TNF-
(BD Pharmingen, San Diego, CA). An IFN- enzyme-linked immunosorbent
assay (ELISA) was performed on supernatants from cultured and stimulated
splenocytes (R&D Systems, Minneapolis, MN). The splenocytes were cultured in
the presence of CD3 and CD28 for 6 h prior to measurement.
Cell surface markers. Spleens were harvested at the time of sacrifice from all
groups of mice. Total cell counts were obtained using a Beckman-Coulter (Ful-
lerton, CA) Vi-Cell cell counter. For specific cell population counts, antibodies
were used to identify lymphocyte subpopulations (CD3 and b220), NK cells,
dendritic cells, and neutrophils (BD Pharmingen, San Diego, CA). Flow cyto-
metric analysis was performed on a FACScan (BD Biosciences, San Jose, CA).
Apoptosis. Apoptosis was quantified using a commercially available antibody
against active caspase 3 (Cell Signaling Technology, Inc., Beverly, MA) and
terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling
(TUNEL) as previously described (21). Mouse T- and B-cell populations were
identified using fluorescein-labeled anti-mouse CD3 and fluorescein-labeled
anti-mouse b220 antibodies (BD Pharmingen, San Diego, CA). Flow cytometric
analysis (50,000 events/sample) was performed on a FACScan (BD Biosciences,
San Jose, CA) as previously described (12).
BAL fluid and blood bacterial counts. Mice were deeply anesthetized with
isoflurane. Following sterile preparation, blood was obtained by direct cardiac
puncture, placed in sterile vials, and diluted from equal volumes for culture. For
bronchoalveolar lavage (BAL), animals were placed supine and the trachea was
exposed by dissection. A 25-gauge angiocatheter was inserted into the trachea,
and 1 ml of sterile saline was injected and immediately withdrawn. The fluid was
placed in sterile vials and diluted from equal volumes for culture.
IFN- blockade. In survival studies using IFN--blocking antibody, 250 g of
antibody or control IgG (clone R4-6A2; BioXcell, West Lebanon, NH) was given
intraperitoneally (i.p.) just prior to secondary injury at 7 days.
Anti-IL-10. The immune modulator AS101 (Tocris, Ellisville, MO), pH. 7.4,
was diluted to an appropriate concentration in PBS (10 g/100 l). For survival
studies, the animals (n  17 per group) received either 10 g AS101 (100 l) or
PBS s.c. starting 24 h after CLP and continuing every 24 h throughout the
survival study. In survival studies using anti-IL-10 antibody, the animals were
given 200 g of anti-IL-10 or control IgG (clone JES5-2A5; BioXcell, West
Lebanon, NH) antibody i.p. at days 1, 3, and 5 post-CLP. For acute studies,
AS101 or PBS was given s.c. in the same manner following CLP until the time of
harvest at 16 h after the induction of pneumonia (n  6 per group). Methods for
measurement of plasma and stimulated cytokines, histology, apoptosis, and BAL
fluid and blood cultures were the same as described above.
Histologic evaluation. Histologic analysis of hematoxylin and eosin (H&E)-
stained lung specimens was performed to confirm the presence of pneumonia.
The degree of infiltration and consolidation was scored by a pathologist (R.E.S.)
blinded to the group assignment. The groups evaluated included animals that
received secondary injury (pneumonia) at 4 and 7 days post-CLP and animals
treated with AS101 (including controls). The scores ranged from 0, representing
no consolidation or infiltration, up to 5, which represented severe infiltration
with multiple areas of consolidation.
Statistical analysis. Student’s t test or the Mann-Whitney U test, whichever
was appropriate, was used for studies in which two groups were compared. For
studies comparing three or more groups, one-way analysis of variance or the
Kruskall-Wallis test was used, whichever was appropriate. The chi-square test
was used for survival studies. Significance was accepted at P  0.05.
Animal studies. Animal studies were approved by the Washington University
School of Medicine Animal Studies Committee.
RESULTS
Analysis of immune cells revealed significant changes in
innate and adaptive cell populations. In order to determine
the changes in immune cell numbers following single injury,
cellular components of the spleen were quantitated at 1, 4, and
7 days post-CLP (including sham-operated controls). Evalua-
tion by flow cytometry revealed significant changes in the cel-
lular composition of whole spleens at these time points. Stain-
ing for cell surface markers revealed that NK cells returned to
sham-operated levels by 4 days following CLP and had signif-
icantly increased by 7 days (P 0.05) (Fig. 1A). Dendritic cells
remained depleted at 4 days but had significantly increased by
7 days (P  0.001) (Fig. 1A). Neutrophils had significantly
increased at both 4 and 7 days following CLP (P  0.01 and
P  0.001, respectively) (Fig. 1A). It should be noted that all
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three innate cell types (NK cells, dendritic cells, and neutro-
phils) showed significant losses following secondary injury at
both 4 and 7 days (data not shown).
Evaluation of T and B lymphocytes revealed significant
changes over the course of 7 days post-CLP compared to their
sham-operated controls. CD4
 lymphocytes had decreased by
day 1 and remained depleted through 7 days (P  0.01) (Fig.
1B), while CD8
 lymphocyte counts were significantly de-
pleted at both 1 and 7 days post-CLP (P  0.001) (Fig. 1B).
Finally, CD20
 B lymphocytes showed a continuous loss over
the 7-day period (P  0.001) (Fig. 1C).
Restoration of stimulated splenocyte IFN- production 7
days post-CLP. Next, we evaluated the ability of splenocytes to
produce IFN- at 4 and 7 days following CLP to determine the
host’s ability to mount an effective inflammatory response prior
to a secondary insult. Following stimulation by CD3 and CD28,
supernatants from harvested and plated splenocytes were mea-
sured for IFN-. The IFN- measurements revealed an 8-fold
FIG. 1. Evaluation of immune effector cells from spleens harvested from sham-operated mice 1 day after CLP (CLP 1d), 4 days after CLP (CLP
4d), and 7 days after CLP (CLP 7d). (A) NK cells returned to sham-operated levels by 4 days following CLP and had significantly increased by
7 days; dendritic cells remained depleted at 4 days but had significantly increased by 7 days. Neutrophils had significantly increased at both 4 and
7 days following CLP. (B) CD4
 lymphocytes had significantly decreased by 1 day and remained depleted through 7 days compared to
sham-operated animals, while CD8
 lymphocyte counts were significantly depleted at 1 and 7 days post-CLP. (C) CD20
 B lymphocytes showed
continuous loss over the 7-day period. n  10 per group (except n  6 for neutrophils). The error bars indicate standard deviations.
FIG. 2. Splenocytes from animals harvested and stimulated just
prior to secondary pneumonia infection at 4 days (96 h after CLP)
revealed significant decreases in IFN- secretion compared to spleno-
cytes from sham-operated animals or animals 7 days post-CLP. , P 
0.01; n  6 per group. The error bars indicate standard deviations.
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increase in the supernatant from animals 7 days post-CLP
compared to 4-day animals and a 2-fold increase compared to
sham-operated animals (Fig. 2).
Enhanced survival of mice infected with pneumonia 7 days
following induction of CLP. Given the significant changes in
the immune cell composition of the spleen at selected time
points and the exaggerated return of IFN- production post-
CLP (7 days), the survival differences in animals undergoing
secondary infection at 4 and 7 days postinjury were evaluated.
Peritonitis induced by CLP with a 30-gauge needle alone or
pneumonia induced by P. aeruginosa (0.3, 0.5, or 0.7 A600)
alone resulted in 85 to 95% survival (data not shown) at 7 days.
We then evaluated the survival of mice given P. aeruginosa
pneumonia at the three different densities administered 4 and
7 days following induction of CLP. Animals receiving CLP
followed by the induction of pneumonia at 4 days at 0.3-A600
density showed an 80% survival at 7 days after induction of
pneumonia, 0.5 A600 resulted in 35% survival, and 0.7 A600
resulted in 20% survival (P  0.006) (Fig. 3A). Animals in-
fected with pneumonia (all three densities) 7 days after CLP
had survival rates similar to those of animals receiving CLP or
pneumonia alone (85%) (Fig. 3B).
IFN- blockade prior to secondary injury abrogates survival
at 7 days post-CLP. Having found significant differences in
IFN- production and survival between animals receiving sec-
ondary injury at 4 versus 7 days post-CLP, we performed sur-
vival experiments looking at the blockade of IFN- prior to
secondary injury at 7 days. When an IFN--blocking antibody
was given just prior to secondary injury, we saw a significant
increase in mortality compared to animals receiving an IgG
control antibody (33.3% versus 88.9%; P  0.028) (Fig. 4).
Increases in lymphocyte apoptosis following primary and
secondary injury. Following septic injury, there is a significant
loss of immune cells by apoptosis. Evaluation of apoptosis by
flow cytometry demonstrated significant changes in levels of
immune cell death following septic injury by both caspase 3
and TUNEL staining. In animals undergoing CLP alone, anal-
ysis of T-cell apoptosis at 4 days revealed significant increases
in both caspase 3 and TUNEL (18.6 versus 1.9% and 12.0
versus 1.2%, respectively; P 0.001) (Fig. 4). CLP followed by
the induction of pneumonia at 4 days (0.5 McFarland stan-
dard) had an additive effect, as these animals, when evaluated
on day 5 (16 h postpneumonia), had even greater levels of
apoptosis (24.8 versus 18.6% [P  0.05] and 19.2 versus 12%
[P  0.01]) (Fig. 4). By 7 days post-CLP, there was a reduction
of T-cell apoptosis in both single- and double-injury animals,
i.e., CLP at 7 days and CLP followed by the induction of
pneumonia on day 7. Similar to 4-day animals, double-injury
animals at 7 days had an increase in T-cell apoptosis compared
to their single-injury counterparts. However, double-injury an-
imals at 7 days compared to 4 days had significantly decreased
FIG. 3. (A) Animals that underwent secondary pneumonia infec-
tion 4 days after CLP showed increasing mortality with increasing
doses of P. aeruginosa (Pa) (0.3 A600  5 10
8 CFU/ml, 0.5 A600  1
109 CFU/ml, and 0.7 A600  3  10
9 CFU/ml; P  0.006). (B) Animals
that underwent secondary pneumonia at 7 days post-CLP showed no
significant difference in survival with increasing doses of bacteria. McF,
McFarland standard.
FIG. 4. Animals 7 days post-CLP and under IFN- blockade at the
time of secondary injury showed increased mortality compared to
control animals. P  0.028; n  9 per group. Pseudo, P. aeruginosa.
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levels of T-cell apoptosis (18.6 versus 12.3% and 12.0 versus
8.3%; P  0.001) (Fig. 5).
Analysis of B-cell apoptosis in spleens at 4 days postinjury
revealed increases in apoptosis in animals undergoing CLP
alone. As seen in the T cells, CLP followed by the induction of
pneumonia at both 4 and 7 days had an additive effect upon
injury-related cell death. The overall pattern of decreased
apoptosis by 7 days in both single- and double-injury animals
was also seen in B cells by TUNEL; however, caspase 3 stain-
ing revealed similar levels of apoptosis.
Cytokine profiles are dependent on the timing of the sec-
ondary injury. Primary sepsis induces a profound production
of circulating cytokines, both pro- and anti-inflammatory. Fol-
lowing a second septic insult, evaluation of plasma cytokines
revealed differences in cytokine levels that were dependent on
the timing of the secondary injury. Animals undergoing P.
aeruginosa pneumonia at 4 days post-CLP had very low levels
of inflammatory cytokines, including IL-1, IL-6, IFN-, and
G-CSF, and higher levels of the anti-inflammatory cytokine
IL-10 16 h after secondary injury (Fig. 6). In contrast, animals
infected with pneumonia 7 days post-CLP had significant in-
creases in IL-1, IL-6, and G-CSF compared to animals in-
fected with pneumonia at 4 days (880 versus 223 pg/ml, 903
versus 188 pg/ml, and 5,139 versus 1,321 pg/ml, respectively;
P  0.01). Seven-day animals also had no increase in IL-10
16 h after the induction of pneumonia (Fig. 6).
Systemic and localized bacterial growth. The immunoparaly-
sis caused by sepsis is associated with a decreased ability of the
host to clear bacteria. Given this, we evaluated the ability of the
host to clear P. aeruginosa from the lungs and blood following
FIG. 5. Following septic injury, there is significant loss of immune cells by apoptosis. In animals that underwent CLP alone, analysis of splenic
T-cell apoptosis at 4 days revealed significant increases in both caspase 3 and TUNEL. CLP followed by the induction of pneumonia at 4 days (0.5
McFarland standard) had an additive effect, as these animals, when evaluated on day 5 (16 h after the induction of pneumonia), had even greater
levels of apoptosis. By 7 days post-CLP, there was a reduction of T-cell apoptosis. Similar to 4-day animals, double-injury animals at 7 days had
an increase in T-cell apoptosis compared to their single-injury counterparts. Double-injury animals at 7 days compared to 4 days had significantly
decreased levels of T-cell apoptosis. Analysis of B-cell apoptosis from spleens at 4 days postinjury revealed significant increases in apoptosis in
animals that underwent CLP alone. As seen in the T cells, CLP followed by the induction of pneumonia at both 4 and 7 days had an additive effect
upon injury-related cell death. n  6 per group. The error bars indicate standard deviations.
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single and double injury. Animals undergoing the induction of
pneumonia alone had no bacteria recovered from their blood and
2 log10 CFU (100 CFU) recovered by BAL (Fig. 7). Animals
undergoing CLP followed by P. aeruginosa infection at 4 days
were found to have significant increases of bacterial growth in
both blood and BAL fluid compared to single-injury animals and
animals infected with pneumonia 7 days following CLP (Fig. 7)
(P  0.001). Consistent with improvement in survival, animals
infected with pneumonia 7 days following CLP had a signif-
icant reduction in the bacterial load in both the blood and
BAL fluid (P  0.001) (Fig. 7). As expected, no P. aerugi-
nosa was recovered from the blood or lungs of animals
receiving CLP or sham surgery alone (Fig. 7).
Decreased lung infiltration and consolidation in 7-day ani-
mals. Light microscopy examination of lungs from double-injury
animals at both 4 and 7 days were scored by a pathologist blinded
to the group assignment. Analysis of lung sections revealed sig-
nificant decreases in lung infiltration and consolidation in animals
receiving secondary injury 7 days post-CLP (3.3  0.75 versus
1.9  0.31; P  0.04) (Fig. 8).
Inflammatory cytokine modulation increases survival after
secondary injury. Researchers have previously shown the
importance of IL-10 as a classic anti-inflammatory cytokine
(34). More importantly, it has been reported that the im-
mune modulator AS101, by its direct inhibition of IL-10
production, can increase survival in multiple models of in-
fection, including single-injury CLP (16). Given that immu-
nosuppression, as evidenced by elevated levels of IL-10 cou-
pled with decreased inflammatory cytokine levels, appeared
to be a key factor in survival at 4 days post-CLP, we explored
the effect of IL-10 inhibition by AS101 or an anti-IL-10
antibody in our two-hit model of sepsis. Mice were given
daily injections of AS101 starting 24 h after CLP and con-
tinuing through the induction of P. aeruginosa pneumonia at
4 days post-CLP. Mice receiving anti-IL-10 antibody were
treated on days 1, 3, and 5 following CLP.
Survival. Treatment with AS101 following CLP signifi-
cantly improved survival following secondary injury (89%
versus 54% survival; P  0.017) (Fig. 9A). Treatment with
anti-IL-10 antibody following CLP improved survival after
FIG. 6. Following a second septic insult, evaluation of plasma cytokines revealed differences in cytokine levels that were dependent on the
timing of the secondary injury. Animals infected with P. aeruginosa pneumonia at 4 days post-CLP had very low levels of IL-1, IL-6, IFN-, and
G-CSF and higher levels of the anti-inflammatory cytokine IL-10. Animals that were infected with pneumonia 7 days post-CLP had significant
increases in IL-1, IL-6, and G-CSF compared to animals that underwent pneumonia infection at 4 days. Seven-day animals also had no increase
in IL-10 16 h after the induction of pneumonia. n  6 per group. The error bars indicate standard deviations. ns, not significant.
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secondary injury similar to that seen in animals treated with
AS101 (87% versus 40% survival; P  0.011) (Fig. 9B).
Apoptosis. Analysis of T and B splenocytes at 16 h post-
secondary infection revealed a decrease in levels of apop-
tosis in animals treated with AS101 compared to controls.
Staining of splenic T-cell and B-cell subpopulations for
caspase 3 showed decreased levels of apoptosis 16 h post-
secondary injury (5.4% versus 9.2% and 5.0% versus 7.5%,
respectively; P  0.03) (data not shown).
Cytokine analysis. Analysis of plasma cytokines revealed a
significant decrease in IL-10 and a significant increase in IL-1
and IL-12p40 in animals treated with AS101 (31 pg versus 229
FIG. 7. BAL fluid and blood cultures showed increased growth in animals that underwent secondary pneumonia infection 4 days post-CLP
compared to 7-day double-injury or single-injury animals. *, P  0.001. n  10 per group. The error bars indicate standard deviations.
FIG. 8. (A) Light microscopic examination was performed on lung specimens harvested 18 h following the induction of pneumonia. Animals
infected with pneumonia 4 days following CLP showed increased consolidation of tissue with extensive polymorphonuclear and mononuclear cell
infiltration compared to animals infected with pneumonia 7 days post-CLP. (B) Evaluation of light microscopy by a pathologist blinded to sample
identity revealed significantly decreased scores for infiltration and consolidation in animals infected with pneumonia 7 days after CLP. P  0.04;
n  6 per group. The error bars indicate standard deviations.
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pg/ml, 408 pg versus 108 pg/ml, and 291 pg versus 17 pg/ml,
respectively; P  0.003) (Fig. 10A). In addition, the ability to
restore splenocyte IFN- production following IL-10 blockade
was examined. Splenocytes from AS101-treated animals har-
vested 4 days after CLP (just prior to secondary injury) showed
a 2.5-fold increase in IFN- production compared to untreated
CLP animals (P  0.001) (Fig. 10B).
BAL and blood culture. Previous literature had shown that
high levels of IL-10 were associated with decreased bacterial
clearance and increased spread of infection and that modula-
tion of IL-10 could improve bacterial clearance (15, 16, 34).
Given these data, we evaluated BAL fluid and blood cultures
from animals that received AS101 and compared them to con-
trol animals at 16 h post-secondary injury. Treatment with
AS101 resulted in decreased bacterial growth from both BAL
fluid and blood compared to animals receiving PBS alone (1.1
versus 2.9 log10 CFU and 0.03 versus 1.6 log10 CFU, respec-
tively; P  0.03) (Fig. 11).
Histology. Light microscopy examination of lungs from dou-
ble-injury animals treated with AS101 was compared to that of
animals treated with vehicle alone. Lungs from control animals
revealed increased consolidation, with extensive polymorpho-
nuclear and mononuclear cell infiltration (Fig. 12A). Scoring
by a pathologist who was blinded to sample identity on a 0- to
5-point scale revealed significantly increased infiltration and
consolidation in the control group (3.3  1.3 versus 1.8  1.03;
P  0.05) (Fig. 12B).
DISCUSSION
In the current study, we first demonstrated that survival in a
clinically relevant two-hit model of sepsis was dependent upon
the timing of the secondary injury. This time-dependent sur-
vival was associated with a dynamic, evolving immune system
that exhibited significantly different phenotypes at 1, 4, and 7
days postinjury. Several important characteristics should be
noted. These changes include differences in splenocyte cell
composition, cytokine production (plasma and stimulated IFN-
), and levels of apoptosis. Consistent with previous studies,
sepsis (in this case CLP) induced an early inflammatory profile
that was dominated by a hyperinflammatory phenotype that,
over time, shifted to a profound hypoinflammatory phenotype
(10, 27). As evidenced by the current study, this state of im-
munoparalysis lasts at least 4 days, followed by a partial recon-
stitution of the immune response by day 7 post-CLP. As a
result of this reconstitution at the 7-day time point, mice chal-
lenged with pneumonia at 7 days had improved survival com-
pared to that for mice challenged at 4 days. This increased
survival at 7 days post-CLP was associated with significantly
decreased pulmonary and circulating blood bacterial counts.
Furthermore, we demonstrated the ability to alter the immune
response within the 4-day hypoinflammatory window. Through
the administration of the immune modulator AS101, we were
able to alter the immune response by decreasing IL-10, in-
creasing IL-1 and IL-12p40, and restoring the ability of
splenocytes to make IFN-. These changes in the immune
profile were associated with decreased growth of P. aeruginosa
from the lungs and blood of treated animals. Finally, AS101
therapy following CLP led to significantly increased survival
when the host was subjected to a secondary injury. This im-
proved survival benefit was also seen in animals treated with an
IL-10-blocking antibody.
Evaluation and characterization of the complex immune re-
sponse in sepsis has led to a better understanding of both the
hyper- and hypoinflammatory states. Many researchers now
postulate that the signals for both the hyper- and hypoinflam-
matory responses begin concurrently in the early stages of
sepsis; however, the timing and mechanisms that determine
whether the host’s phenotype is hyperinflammatory or immu-
nosuppressed are less well understood (10, 30). The current
study again establishes that risk of infection is increased when
the host is in a state of relative anergy or immunosuppression.
More importantly, the current findings provide evidence that
the severity of and survival after a secondary infection depend
upon the time of onset and the immunologic state of the host.
The relative abundances of pro- and anti-inflammatory cyto-
kines are thought to have a critical effect on how immune
effector cells respond to infection. During the hyperinflamma-
FIG. 9. (A) Treatment with AS101 following CLP significantly im-
proved survival after secondary injury; P  0.017; n  17 per group.
(B) Treatment with anti-IL-10 antibody following CLP improved sur-
vival after secondary injury similar to that seen in animals treated with
AS101. P  0.011; n  15 per group.
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tory-dominated stage of the septic response, cytokines such as
IL-6, IFN-, TNF, and IL-12, have been shown to mediate
bacterial clearance and upregulate immune effector cell func-
tion (18, 23). During the immunosuppressive phase of sepsis,
cytokines such as IL-4 and IL-10 lead to suppression of mac-
rophage cytokine secretion and decreased activity of macro-
phage and neutrophil functions (4, 20, 34). The current study
has demonstrated that survival after a secondary injury is de-
pendent on the ability of the host to mount an effective im-
mune response. Four days following the initial injury, animals
are unable to produce inflammatory cytokines in response to a
secondary insult, including failure of stimulated splenocytes to
produce IFN-. However, when that insult is given at 7 days
after the initial injury, the host is able to produce high enough
levels of inflammatory cytokines to overcome the secondary
infection. This need for an inflammatory response to secondary
injury to improve survival is also supported by our survival
study showing that blocking of IFN- just prior to the second-
ary injury removes the survival benefit seen at 7 days post-CLP.
The importance of IFN- production in response to infection
has been demonstrated by multiple authors. Hotchkiss et al.
showed in adoptive transfer experiments that increased sur-
vival of animals receiving necrotic cells following CLP was due
to the upregulation of IFN-, as this survival benefit was lost in
FIG. 10. (A) Blood collected 18 h following the induction of pneumonia showed significantly decreased plasma IL-10 and significantly increased
IL-1 and IL-12p40 levels in animals treated with AS101. *, P  0.003. (B) Splenocytes from animals treated with AS101 showed significant
increases in IFN- production compared to controls 4 days post-CLP; *, P  0.001. n  6 per group. The error bars indicate standard deviations.
FIG. 11. BAL fluid and blood cultures showed decreased growth with AS101 treatment versus vehicle. *, P  0.03. n  6 per group. The error
bars indicate standard deviations.
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IFN- knockout animals or in animals treated with an anti-
IFN- antibody (11). The clinical importance of IFN- was
described by Docke et al., who showed that treatment with
IFN- in septic patients restored monocyte activation and im-
proved the clinical course (3).
In addition to changes in cytokine production, multiple re-
search studies of animal models and patients dying from sepsis
have demonstrated profound loss of immune effector cells by
apoptosis (9, 10, 13, 36). This loss of lymphocytes and dendritic
cells is thought to be partially responsible for the profound im-
munosuppression seen in sepsis (6, 9, 10). Recovery of specific
immune cell populations in sepsis is likely correlated with im-
proved outcome. However, the mechanisms by which these cel-
lular compartments recover in sepsis are poorly understood. In
this study, we demonstrated that there is a continued loss of
lymphocytes following the initial injury; however, the innate cell
populations in the spleen revealed that neutrophils and NK cells
were increased over baseline by 4 days. Furthermore, dendritic
cells, although still depleted at 4 days, were 2-fold above baseline
levels by 7 days. We speculate that this return of innate cells,
particularly dendritic cells, may be a global marker of immune
status and correlated with the hyperinflammatory, prosurvival
response seen in animals undergoing secondary injury at 7 days.
Future studies, including depleting and/or adoptive transfer of
these cell types, may further characterize the role these innate
cells play in determining the immune profile of the host.
Our hypothesis that immunosuppression at 4 days is a sig-
nificant contributor to decreased survival when faced with a
secondary bacterial challenge is further supported by results
showing that blocking of IL-10 by AS101 improves the out-
come. IL-10 has been shown by others to be an important
mediator of immune function and is known to downregulate
monocyte and neutrophil functions, as well as to decrease
inflammatory cytokine production by T cells (33, 34). Consis-
tent with work by Kalechman et al., who showed that admin-
istration of AS101 at least 6 h post-CLP improved survival and
immune cell function, the present work showed that blockage
of IL-10 by AS101 is equally efficacious in a two-hit model (16).
This finding is particularly important because in many inten-
sive-care units the majority of sepsis-related deaths are due to
secondary nosocomial infections. However, these results are
different than those suggested by Murphey and Sherwood, who
showed that mice that underwent anti-IL-10 treatment or
IL-10 knockout mice did not have improved bacterial clear-
ance or survival in a two-hit model (24). Given these disparate
findings, we evaluated survival in our model using an anti-
IL-10 antibody in order to show that the primary survival
benefit of AS101 treatment was its ability to downregulate
FIG. 12. (A) Light microscopic examination was performed on lung specimens harvested 18 h following the induction of pneumonia. Control
animals showed increased consolidation of tissue with extensive polymorphonuclear and mononuclear cell infiltration. (B) Evaluation of light
microscopy by a pathologist blinded to sample identity revealed significantly decreased scores for infiltration and consolidation in animals treated
with AS101. , P  0.05; n  6 per group. The error bars indicate standard deviations.
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IL-10. As a result, our model showed improved survival in
animals treated with anti-IL-10 antibody, similar to what was
observed in AS101-treated animals. In addition, there are sev-
eral differences between the model described here and the
model used by Murphey and Sherwood (24). First, Murphey
and Sherwood used a primary CLP injury with a mortality of
around 50% compared to our study, in which CLP alone pro-
duced 90% survival. Next, in their study, intravenous Pseudo-
monas alone led to 75% mortality, whereas our secondary
injury, when given alone intranasally, produced 90% survival.
Finally, Murphey and Sherwood gave the second injury 5 days
post-CLP (24). These differences in study design, particularly
the large disparities in survival after a single injury and the route
of administration, would likely lead to changes in the hyper-/
hypoinflammatory axis. It is also important to note that AS101
has other effects that may account for some of the findings de-
scribed here. Strassman et al., who evaluated the effect of AS101
on mouse peritoneal macrophages, found that it inhibits the pro-
duction of IL-10 at the mRNA level and also augments levels of
IL-1 and TNF- (35). Our work found significant alterations in
IL-1 but no differences in TNF- levels.
In conclusion, our findings provide further understanding of
the development and recovery from sepsis-induced immuno-
suppression. Given the continued impact of sepsis syndromes
and risks of secondary infection on morbidity and mortality, it
is important to continue to develop therapeutic strategies that
modulate the hyperinflammatory/hypoinflammatory axis. Ad-
ditionally, a better understanding of the host’s current immune
status may be useful when determining specific goal-oriented
therapies. Modulation of IL-10 may be one specific target for
drug development to favorably alter the host immune status.
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